Patent US4460562A successfully refreshed from Google Patents.
US4460562A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Polymeric diffusion matrix containing propranolol
Assignee: Key Pharmaceuticals Inc
•
Filing: 1983-03-30
•
Granted: 1984-07-17
•
Expires: 2003-03-30
Abstract
Abstract A self-supporting polymeric diffusion matrix provides for the sustained release of propranolol in order to deliver the propranolol to a patient. The matrix comprises from about 1 to about 60% of a polar plasticizer, from about 6 to about 30% by weight polyvinylalcohol, from about 2 to about 30% by weight polyvinylpyrrolidone, and a pharmaceutically effective amount of propranolol to provide a sustained release of propranolol over a prolonged period.
Inventors
- 👤 Alec D. Keith
- 👤 Wallace Snipes
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 14:09
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7084; A61K31/00; A61K31/13; A61K31/135; C; C07; C07K; C07K2319/00; C07K2319/01; C07K2319/02; C07K2319/55; C07K2319/70; C07K2319/74
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
108 words
A self-supporting polymeric diffusion matrix for the sustained release of propranolol to deliver transdermally said propanolol to a patient in need of a beta-andrenergic blocking agent, said matrix comprising from about 1 to about 60% of a polar plasticizer, from about 6 to about 30% by weight of at least 90% hydrolyzed polyvinyl alcohol molecular weight of about 50,000 to about 150,000, from about 2 to about 30% by weight polyvinylpyrrolidone molecular weight of about 15,000 to about 85,000, and a pharmaceutically transdermally effective amount of propanolol, a beta-adrenergic blocking agent indicated for the control of hypertension, arrhythmias and migraine, when applied to the skin of said patient.
Claim 2
Dependent Claim
108 words
A self-supporting polymeric diffusion matrix for the sustained release of propranolol to deliver transdermally said propanolol to a patient in need of a beta-andrenergic blocking agent, said matrix comprising from about 1 to about 60% of a polar plasticizer, from about 6 to about 30% by weight of at least 90% hydrolyzed polyvinyl alcohol molecular weight of about 50,000 to about 150,000, from about 2 to about 30% by weight polyvinylpyrrolidone molecular weight of about 15,000 to about 85,000, and a pharmaceutically transdermally effective amount of propanolol, a beta-adrenergic blocking agent indicated for the control of hypertension, arrhythmias and migraine, when applied to the skin of said patient.
Claim 3
Dependent Claim
31 words
The polymeric diffusion matrix of claim 1, wherein the total content of polyvinylalcohol and polyvinylpyrrolidone is from about 25 to about 60% by weight, based on the weight of the matrix.
Claim 4
Dependent Claim
13 words
The polymeric diffusion matrix of claim 1, wherein the polar plasticizer is glycerol.
Claim 5
Dependent Claim
24 words
The polymeric diffusion matrix of claim 1, wherein the polar plasticizer is polyethylene glycol present in an amount of about 1 to about 15%.
Claim 6
Dependent Claim
21 words
The polymeric diffusion matrix of claim 1, wherein the polyvinyl alcohol has a molecular weight of about 100,000 to about 150,000.
Claim 7
Dependent Claim
20 words
The polymeric diffusion matrix of claim 5, wherein the polyvinylpyrrolidone has a molecular weight of about 20,000 to about 60,000.
Claim 8
Dependent Claim
43 words
The polymeric diffusion matrix of claim 6, wherein the polar plasticizer is a mixture of glycerol and polyethylene glycol, and the polyethylene glycol is present in an amount by weight of from about 1 to 5 parts per weight per part of glycerol.
Claim 9
Dependent Claim
47 words
The polymeric diffusion matrix of claim 7, comprising about 20% by weight polyvinyl alcohol of molecular weight about 115,000, about 15% by weight of polyvinylpyrrolidone of molecular weight about 40,000, about 5% by weight polyethylene glycol of molecular weight about 4000, and about 3% by weight glycerol.
References Cited (Backward Citations)
US2138751A
Cited
US2155658A
Cited
US2160503A
Cited
US2127896A
Cited
US2340866A
Cited
US2491642A
Cited
US2693438A
Cited
GB933668A
Cited
US3287222A
Cited
FR1505318A
Cited
US3249109A
Cited
SU219116A1
Cited
GB1108837A
Cited
US3598123A
Cited
FR2245161A6
Cited
US3742951A
Cited
US3742951B1
Cited
JPS4892522A
Cited
JPS4930525A
Cited
JPS4945952A
Cited
JPS4948728A
Cited
JPS5056385A
Cited
JPS51112511A
Cited
US3972995A
Cited
US4076798A
Cited
JPS5238016A
Cited
JPS5350320A
Cited
GB2021950A
Cited
FR2437830A1
Cited
US4210633A
Cited
US4394390A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-07-17 | 1988-01-16 | 1988-07-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-07-17 | 1992-01-16 | 1992-07-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-07-17 | 1996-01-16 | 1996-07-17 | $7700.00 | Window Closed / Lapsed |